1. Guidance for the industry: expedited programs for serious conditions – Drugs and Biologicals. US Department of Health and Human Sciences. Food and Drug Administration. Center for Drug Evaluation and Research,2014
2. EMA approval of Esketamine for the treatment of treatment resistant depression. December 2019
3. FDA approval of Esketamine for the treatment of treatment resistant depression. March 2019
4. Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life;Goodwin;JAD,2023
5. The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development;Krystal;Nat. Rev. Drug Discov.,2018